The Polaris Group, LLC is a Cayman Islands-based company, which is primarily engaged in biotechnology services, drug testing, contract development and manufacturing services and research, development, manufacture and sales of new drugs. The Companyâ€™s core research is ADI-PEG 20, which is undergoing human clinical trials for various cancer indications. The ADI-PEG 20 is a biologic in late-stage clinical development for a wide range of cancers, including hepatocellular carcinoma, mesothelioma, pancreatic cancer, non-small cell lung cancer, melanoma, acute myeloid leukemia, and others. ADI-PEG 20 is a biological drug produced by coupling arginine deiminase and polyethylene glycol with a molecular weight of 20,000.

Employees

Sector

Biotechnology & Medical Research

Calendar

03-12 - Q4 2025 Earnings Release (Projected)

More about the company

Quotes

Date	Price	Change	Volume
11/02/26	29.90 NT$	+2.22%	902,575
10/02/26	29.25 NT$	+0.34%	826,398
09/02/26	29.15 NT$	-2.83%	1,758,682
06/02/26	30.00 NT$	-3.54%	1,466,532
05/02/26	31.10 NT$	-1.11%	1,628,785

End-of-day quote Taiwan S.E.

More quotes

Income Statement and Estimates

More financial data

Select your edition

All financial news and data tailored to specific country editions

NORTH AMERICA

United-States

Canada

End-of-day quote Taiwan S.E. Other stock markets 11/02/2026			5-day change	1st Jan Change
29.90 ^TWD	+2.22%		-3.86%	-3.86%

12-26	Polaris Group Announces Management Changes, Effective December 26, 2025	CI
12-26	Polaris Group Announces Chief Executive Officer Changes, Effective December 26, 2025	CI

Capitalization	23.96B 762M 642M 586M 560M 1.04B 69.06B 1.07B 6.81B 2.71B 33.27B 2.86B 2.8B 116B	P/E ratio 2023	-35.6x	P/E ratio 2024	-13.6x
Enterprise value	23.97B 763M 643M 586M 560M 1.04B 69.09B 1.08B 6.81B 2.71B 33.29B 2.86B 2.8B 116B	EV / Sales 2023	7,151,545,988x	EV / Sales 2024	318,439,381x
Free-Float	35.26%	Yield 2023 *	-	Yield 2024	-

12-26	Polaris Group Announces Management Changes, Effective December 26, 2025	CI
12-26	Polaris Group Announces Chief Executive Officer Changes, Effective December 26, 2025	CI
12-25	Polaris Group announced that it expects to receive TWD 3.2 billion in funding	CI
12-17	Polaris Group's CEO Resigns	MT
12-16	Polaris Group Announces Resignation of Steve J.P. Hsu as Chief Executive Officer, Effective December 24, 2025	CI
12-16	Polaris Group Names New Chairman; Shares Rally 10%	MT
12-15	Polaris Group Announces Management Changes, Effective December 24, 2025	CI
11-12	Polaris Group Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025	CI
01/09/25	Polaris Group Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2025	CI
19/08/25	Polaris Cancer Drug Candidate Enters FDA Substantive Review	MT
21/07/25	Polaris Unit Grants Drug Distribution Rights to Bioprofarma Bago	MT
11/06/25	Polaris Group Completes Submission of US FDA Application for Rare Lung Cancer Drug	MT
10/06/25	Polaris Group Completes Rolling Submission of Biologic License Application for ADI-PEG 20 with FDA to Treat Malignant Pleural Mesothelioma	CI

22/12/23	Polaris Group Announced the Acquisition of Genovior Biotech, Initiating Dual-Engine Growth	GL
04/12/23	Polaris Group Initiates Phase 3 Trial: First Patient Successfully Dosed with ADI-PEG 20/Placebo plus Gemcitabine and Docetaxel for Difficult-to-Treat Leiomyosarcoma (LMS)	AQ
04/12/23	Polaris Group Initiates Phase 3 Trial: First Patient Successfully Dosed with ADI-PEG 20/Placebo plus Gemcitabine and Docetaxel for Difficult-to-Treat Leiomyosarcoma (LMS)	GL
30/11/23	Polaris Group Announces First Patient Successfully Dosed with ADI-PEG 20/Placebo in Phase 2a Non-Alcoholic Steatohepatitis (NASH) Study	GL
17/11/23	Polaris Group Initiates Rolling Submission of Biologic License Application (BLA) for ADI-PEG 20 with U.S. FDA to Treat Malignant Pleural Mesothelioma	GL

Polaris Group Share Price

Equities

6550

KYG7171A1085

Biotechnology & Medical Research

Valuation: Polaris Group

Chart: Polaris Group

Latest news: Polaris Group

Press Releases: Polaris Group

Quotes and Performance

Course Extremes

Managers and Directors: Polaris Group

Other Biotechnology & Medical Research

Financials

Company Profile

Quotes

Income Statement and Estimates

1 day	+2.22%
1 week	-3.86%
Current month	-3.55%
1 month	-3.39%
3 months	-4.47%
6 months	-16.83%
Current year	-3.86%

1 week	28.75	30.3
1 month	28.75	33.95
Current year	28.75	33.95
1 year	26.35	51.6
3 years	26.35	103.5
5 years	15.9	232
10 years	9.5	232

Manager	Title	Age	Since
Lan Ying Huang DFI	Director of Finance/CFO	-	28/02/2019
Wei Yuan Lin COO	Chief Operating Officer	-	31/01/2019
Shao Chen Chen CEO	Chief Executive Officer	-	30/04/2014

Director	Title	Age	Since
Patrick Yang BRD	Director/Board Member	78	-
Hung Wen Chen CHM	Chairman	-	23/11/2014
Samuel Chen BRD	Director/Board Member	75	24/02/2020

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5d. change	1-year change	3-years change	Capi.($)
POLARIS GROUP	+2.22%	-3.86%	-38.35%	-70.54%	733M
LONZA GROUP AG	+3.82%	-0.54%	-13.98%	-5.61%	45.48B
BEONE MEDICINES AG	-1.38%	-0.17%	+55.13%	+41.70%	38.33B
CELLTRION, INC.	-0.42%	+9.66%	+38.80%	+60.37%	36.26B
IQVIA HOLDINGS INC.	-4.70%	-6.69%	-14.64%	-24.23%	28.64B
REVOLUTION MEDICINES, INC.	-0.67%	+1.23%	+131.74%	+295.97%	18.82B
IONIS PHARMACEUTICALS, INC.	-3.05%	-2.04%	+165.18%	+109.69%	13.25B
ASCENDIS PHARMA A/S	-1.53%	+0.33%	+72.90%	+91.40%	13.39B
EUROFINS SCIENTIFIC SE	+2.19%	-3.79%	+29.54%	-3.08%	13.41B
REGENCELL BIOSCIENCE HOLDINGS LIMITED	+8.61%	+15.76%	+29,391.87%	+3,835.45%	14.35B
Average	+0.51%	+0.26%	+2,981.82%	+433.11%	22.27B
Weighted average by Cap.	+0.23%	+0.30%	+1,932.40%	+296.56%

	2023	2024
Net sales	7.48 0.24 0.2 0.18 0.17 0.32 21.56 0.34 2.13 0.85 10.39 0.89 0.87 36.28	107 3.4 2.87 2.62 2.5 4.64 308.41 4.8 30.41 12.09 148.58 12.77 12.5 518.9
Net income	-1.58B -50.16M -42.27M -38.58M -36.82M -68.38M -4.54B -70.72M -448M -178M -2.19B -188M -184M -7.65B	-2.5B -79.62M -67.09M -61.23M -58.45M -109M -7.21B -112M -711M -283M -3.48B -299M -292M -12.14B
Net Debt	-2.71B -86.06M -72.52M -66.19M -63.18M -117M -7.8B -121M -769M -306M -3.76B -323M -316M -13.12B	9.19M 292K 246K 225K 215K 399K 26.49M 412K 2.61M 1.04M 12.76M 1.1M 1.07M 44.58M